MiniMed Continuous Glucose Monitor Rollout Expanding To 30 Centers In Q4
This article was originally published in The Gray Sheet
Executive Summary
Expanded roll-out of MiniMed's continuous glucose monitor system to twenty-one additional U.S. centers will be completed by the end of November, the firm says.
You may also be interested in...
MiniMed's Model 508
Next-generation insulin infusion pump for diabetics, introduced Oct. 4, offers remote programming capabilities to administer or suspend insulin delivery and the capability to program multiple patient-specific delivery patterns. The device gained FDA 510(k) clearance in June
Minimed
Launches Model 407C infusion pump for general medication use following 510(k) clearance June 23. Similar to the firm's insulin infusion pumps and designed to deliver medications suitable for subcutaneous administration, the 407C represents diversification of the firm's technology to include disease states other than diabetes. MiniMed expects the device to be first used in connection with its alliance with United Therapeutics for the treatment of pulmonary hypertension
MiniMed Glucose Monitor Approval Sweet As Stock Gains 30% In June
FDA approval of MiniMed's continuous glucose monitoring system (CGMS) June 16 helped sweeten the company's stock price during the month.